| Literature DB >> 27168725 |
Ana Maria Olivares1, Oscar Andrés Moreno-Ramos2, Neena B Haider1.
Abstract
The nuclear hormone receptor (NHR) superfamily is composed of a wide range of receptors involved in a myriad of important biological processes, including development, growth, metabolism, and maintenance. Regulation of such wide variety of functions requires a complex system of gene regulation that includes interaction with transcription factors, chromatin-modifying complex, and the proper recognition of ligands. NHRs are able to coordinate the expression of genes in numerous pathways simultaneously. This review focuses on the role of nuclear receptors in the central nervous system and, in particular, their role in regulating the proper development and function of the brain and the eye. In addition, the review highlights the impact of mutations in NHRs on a spectrum of human diseases from autism to retinal degeneration.Entities:
Keywords: brain; central nervous system; eye; human disease; nuclear hormone receptors; regulation
Year: 2016 PMID: 27168725 PMCID: PMC4859451 DOI: 10.4137/JEN.S25480
Source DB: PubMed Journal: J Exp Neurosci ISSN: 1179-0695
Figure 1Schematic representation of the functional domains of NHRs in each classification cluster. The A/B domain is the most variable region, and it contains the activation function-1 (AF-1) site. The activation functions AF-1 and -2 are important in the regulation of receptor transcriptional activity. The C domain is one of the most highly conserved regions across the superfamily on nuclear receptors and consists of the DNA-binding region. The D domain, also known as the hinge region, is involved in the conformational changes that occur after ligand binding allowing the coactivators or corepressors to bind. LBD is the second most conserved region and is in charge of the recognition and binding of the ligands. The F region is a carboxyl terminal that is not present in all receptors.2,4,73
Hormone response elements’ (HREs) sequences and their coactivators and cosuppressors.
| NUCLEAR HORMONE RECEPTOR | HRE SEQUENCE | RESPONSE ELEMENT | CO-ACTIVATORS | CO-SUPPRESORS |
|---|---|---|---|---|
| Thyroid hormone receptor alpha (NR1A1) | AGGTCA | NCOA1 | NCOR1 | |
| NCOA2 | NCOR2 | |||
| NCOA3 | ||||
| MED1 | ||||
| Thyroid hormone receptor beta (NR1A2) | AGGTCA | NCOA1 | NCOR1 | |
| NCOA2 | ||||
| NCOA3 | ||||
| Vitamin D receptor | Not known | Not known | ||
| Retinoid acid receptor alpha (NR1B1) | 5′-PuG(G/T)TCA-3′ | Heterodimer | CREBBP | NCOR1 |
| EP300 | NCOR2 | |||
| MED1 | ||||
| NCOA1 | ||||
| NCOA2 | ||||
| NCOA3 | ||||
| Retinoid acid receptor beta (NR1B2) | 5′-PuG(G/T)TCA | Heterodimer | MED1 | |
| NCOA1 | ||||
| NCOA2 | ||||
| NCOA3 | ||||
| Retinoid acid receptor gamma (NR1B3) | 5′-PuG(G/T)TCA-3′ | Heterodimer | NCOA1 | NCOR1 |
| NCOA2 | NCOR2 | |||
| NCOA3 | ||||
| Retinoid X alpha (NR2B1) | 5′-AGGTCA | Homodimer, Heterodimer | CREBBP | |
| EP300 | ||||
| MED1 | ||||
| NCOA1 | ||||
| NCOA2 | ||||
| NCOA3 | ||||
| PPARGC1A | ||||
| TAF11 | ||||
| TAF4 | ||||
| TBP | ||||
| Retinoid X beta (NR2B2) | 5′-AGGTCA | Homodimer, Heterodimer | NCOA1 | |
| NCOA2 | ||||
| NCOA3 | ||||
| PNR (NR2E3) | AAGTCA n AAGTCA | Homodimer | CRX | |
| Retinoid X gamma (NR3B3) | 5′-AGGTCA | Homodimer, Heterodimer | NCOA1 | |
| NCOA2 | ||||
| NCOA3 | ||||
| Farnesoid X receptor (NR1H4) | AGTTCAnTGAACT | CARM1 | ||
| MED1 | ||||
| NCOA1 | ||||
| PPARGC1A | ||||
| PRMT1 | ||||
| TRRAP | ||||
| Farnesoid X receptor beta (NR1H5) | AGTTCA N TGAACT | Heterodimer | NCOA1 | |
| Liver X receptor alpha (NR1H3) | AGGTCANNNNAGGTCA | EP300 | NCOR1 | |
| NCOA1 | NCOR2 | |||
| NCOA2 | ||||
| PPARGC1A | ||||
| PPARGC1B | ||||
| TRRAP | ||||
| Liver X receptor beta (NR1H2) | AGGTCANNNNAGGTCA | EP300 | ||
| NCOA1 | ||||
| NCOR1 | ||||
| PPAR alpha (NR1C1) | 5′-AACTAGGNCA A AGGTCA-3′ | Heterodimer | CITED2 | NCOR1 |
| CREBBP | NRIP1 | |||
| HADHA | ||||
| MED1 | ||||
| NCOA1 | ||||
| NCOA3 | ||||
| NCOA6 | ||||
| PPARGC1A | ||||
| PPARGC1B | ||||
| SMARCA2 | ||||
| PPAR beta (NR1C2) | NCOA1 | NCOR1 | ||
| NCOA3 | NCOR2 | |||
| NCOA6 | ||||
| PPARGC1A | ||||
| PPAR gamma (NR1C3) | 5′-AACTAGGNCA A AGGTCA-3′ | Heterodimer | CITED2 | WWTR1 |
| CREBBP | SAFB | |||
| EP300 | NRIP1 | |||
| MED1 | NCOR2 | |||
| NCOA1 | NCOR1 | |||
| NCOA2 | ||||
| NCOA3 | ||||
| NCOA4 | ||||
| NCOA6 | ||||
| NCOA7 | ||||
| PPARGC1A | ||||
| PPARGC1B | ||||
| PRMT2 | ||||
| SCAND1 | ||||
| SMARCA1 | ||||
| TGS1 | ||||
| PXR/SXR receptor (NR1I2) | AGGTCA | Heterodimer | FOXO1 | NCOR2 |
| GRIP1 | NR0B2 | |||
| NCOA1 | ||||
| NRIP1 | ||||
| PPARGC1A | ||||
| CAR (NR1I3) | AGGTCA | Heterodimer | MED1 | |
| NCOA1 | ||||
| PPARGC1A | ||||
| ROR alpha (NR1F1) | T/A A/T T/A C A/T A/GGGTCA | Monomer, Homodimer | EP300 | HR |
| NCOA2 | NCOR1 | |||
| MED1 | NCOR2 | |||
| ROR beta (NR1F2) | T/A A/T T/A C A/T A/GGGTCA | NCOR1 | NCOR1 | |
| NRIP2 | ||||
| ROR gamma (NR1F3) | AGGTCA nnnnn AGGTCA | NCOA1 | HR | |
| DAS-like receptors | Not known | Not known | ||
| Rev-Erb alpha (NR1D1) | A/T A A/T N T PuGGTCA | NCOA5 | C1D | |
| HDAC3 | ||||
| NCOA5 | ||||
| NCOR1 | ||||
| Rev-Erb beta (NR1D2) | A/T A A/T N T PuGGTCA | NCOA5 | NCOA5 | |
| NCOR1 | ||||
| HNF4 alpha (NR2A1) | CREBBP | NCOR2 | ||
| GRIP1 | ||||
| MED1 | ||||
| PPARGC1A | ||||
| PPARGC1B | ||||
| HNF4 gamma (NR2A2) | AGGTCA n AGGTCA | Not known | Not known | |
| Testicular receptor 2 (NR2C1) | AGGTCA n AGGTCA | Monomer, Homodimer | HDAC3 | |
| HDAC4 | ||||
| NRIP1 | ||||
| Testicular receptor 4 (NR C2) 2 | Monomer, Homodimer, Heterodimer | JAZF 1 | ||
| NR2C2AP | ||||
| Tailless like receptor (NR2E1 and NR2E3) | AAGTCA n AAGTCA | Not known | Not known | |
| COUP-TF1 (NR2F1) | AGGTCA n AGGTCA | CREBBP | BCL11A | |
| NCOA1 | BCL11B | |||
| NCOR1 | ||||
| NCOR2 | ||||
| COUP-TF2 (NR2F2) | A/GGGTCA n AGGGTCA | BCL11B | BCL11A | |
| SQSTM1 | NCOR1 | |||
| NCOR2 | ||||
| ZFPM2 | ||||
| V-erbA-related gene (NR2F6) | AGGTCA n AGGTCA | NCOA1 | ||
| Estrogen-related receptor alpha (NR3B1) | TNA AGGTCA | NCOA1 | ||
| NCOA2 | ||||
| NCOA3 | ||||
| PNRC2 | ||||
| PPARGC1A | ||||
| Estrogen-related receptor beta (NR3B2) | TNA AGGTCA | NCOA1 | ||
| NCOA2 | ||||
| NCOA3 | ||||
| PNRC1 | ||||
| Estrogen-related receptor gamma (NR3B3) | TNA AGGTCA | NCOA1 | ||
| PNRC2 | ||||
| PPARGC1A | ||||
| PPARGC1B | ||||
| TLE1 | ||||
| Nerve growth factor IB-like receptor (NR4A1) | AAAGGTCA | Homodimer, Heterodimer | EP300 | |
| KAT2B | ||||
| NCOA1 | ||||
| NCOA2 | ||||
| NCOA3 | ||||
| MED1 | ||||
| Nuclear receptor related 1 (NR4A2) | AAAGGTCA | Not known | Not known | |
| Neuron-derived orphan receptor 1 (NR4A3) | AAAGGTCA | SIX3 | ||
| MED1 | ||||
| EP300 | ||||
| NCOA2 | ||||
| KAT2B | ||||
| Steroidogenic factor 1 (NR5A1) | YCA AGG YCR | Monomer | CREBBP | NCOR2 |
| EDF1 | ||||
| NCOA1 | ||||
| NCOA2 | ||||
| PNRC2 | ||||
| Liver receptor homolog-1 (NR5A2) | YCA AGG YCR | Monomer | NCOA1 | PROX1 |
| NCOA3 | ||||
| EP300 | ||||
| EID1 | ||||
| Germ cell nuclear factor (NR6A1) | TCA AGGTCA | Homodimer | NCOR1 | |
| NCOR2 | ||||
| SHP (NR0B2) | SIN3A | |||
| HDAC3 | ||||
| HDAC1 | ||||
| EID1 | ||||
| NCOR1 | ||||
| NCOR2 | ||||
| Estrogen receptor-α (NR3A1) | GGTCAnnnTGACC | Homodimer | NCOA1 | NCOR1 |
| NCOA2 | NRIP1 | |||
| NCOA3 | ||||
| CREBBP | ||||
| EP300 | ||||
| MED1 | ||||
| DDX5 | ||||
| SRA1 | ||||
| Estrogen receptor-β (NR3A2) | GGTCAnnnTGACC | Homodimer | NCOA1 | NCOR1 |
| NCOA2 | NRIP1 | |||
| NCOA3 | ||||
| EP300 | ||||
| CREBBP | ||||
| MED1 | ||||
| DDX5 | ||||
| SRA1 | ||||
| Androgen receptor (NR3C4) | GGTACANNNTGTTCT | Homodimer | CARM1 | NCOR1 |
| CCND1 | NCOR2 | |||
| EP300 | ||||
| FHL2 | ||||
| KAT2B | ||||
| KAT5 | ||||
| MED1 | ||||
| NCOA1 | ||||
| NCOA2 | ||||
| NCOA3 | ||||
| NCOA4 | ||||
| RAN | ||||
| RNF14 | ||||
| SMARCD1 | ||||
| TGFB1I1 | ||||
| UBE3A | ||||
| Glucocorticoid receptor (NR3C1) | GGTACANNNTGTTCT | Monomer | CREBBP | BAG1 |
| MED1 | NCOR1 | |||
| NCOA2 | ||||
| NCOA6 | ||||
| PTMS | ||||
| SMARCA1 | ||||
| SMARCD1 | ||||
| TADA2A | ||||
| Mineralocorticoid receptor (NR3C2) | ACAAGANNNTGTTCT | Homodimer, Heterodimer | CASP8AP2 | DAXX |
| ELL | NCOR1 | |||
| EP300 | NCOR2 | |||
| FAF1 | NFYC | |||
| MTL5 | PIAS1 | |||
| NCOA1 | ||||
| NCOA2 | ||||
| NRIP1 | ||||
| PPARGC1A | ||||
| PPARGC1A | ||||
| PPARGC1A | ||||
| TRIM24 | ||||
| UBE2I | ||||
| Progesterone receptor (NR3C3) | GGTACANNNTGTTCT | Homodimer | NCOA3 | |
| SRA1 | ||||
| NCOA1 | ||||
| NCOR2 | ||||
| CREBBP | ||||
| JDP2 |
Figure 2HREs’ potential patterns associated with NHRs. Schematic representation of (A) NHRs binding to HREs and (B) positive HRE and nHRE patterns.
Figure 3Transcription repression or activation mediated by RAR–RXR nuclear receptors. Coregulator binding can alter chromatin structure, aiding gene transcription or blockage via histone acetylation or deacetylation. (A) Transcriptional activation by coactivators NCOA and trithorax and histone acetylation by HAT proteins, in the presence of RA. (B) Transcriptional repression by corepressors NCOR, SMRT, LCOR, and RIP140 and histone deacetylation by HDAC proteins, in the absence of RA.
Figure 4Phylogenetic depiction of the nuclear receptor families. Receptors expressed in the CNS are highlighted in blue.122
Nuclear receptors expressed in the different areas of the human or mouse brain.
| RECEPTOR | LOCATION |
|---|---|
| Pparα | BC, C, BS |
| Pparβ/δ | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Pparγ | OA, BC, CO, C |
| Rxrα | OAM, CP, H, HY, CO, C, BS |
| Rxrβ | OA, BC, H, T, HY, AN, CO, C, BS |
| Rxrγ | OA, BC, CP, H, HY, AN, BS |
| Rorα | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Rorβ | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Rorγ | BC, H, HY, CO, C, BS |
| Tr2 | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Tr4 | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Tlx | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Nurr1 | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Nor1 | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Rarα | OA, BC, CP, H, HY, CO, C, BS |
| Rarβ | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Rarγ | OA, BC, H, HY, CO, C, BS |
| Trα | OA, BC, CO, H, T, HY, CO, C, BS |
| Trβ | OA, BC, CP, H, HY, AN, CO, C, BS |
| Mr | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Ngf1B | OA, BC, CP, H, T, HY, CO, C, BS |
| Nr1d1 | OA, BC, CP, H, T, HY, CO, C, BS |
| Nr1d2 | BC, CP, H, T, HY, AN, CO, C, BS |
| Nr2f1 | OA, BC, T, HY, C, BS |
| Nr2f2 | BC, H, T, HY, CO, C, BS |
| Lxrα | OA, BC, H, HY, AN, CO, C, BS |
| Lxrβ | BC, CP, H, T, HY, AN, CO, C, BS |
| Lxrγ | OA |
| Vdr | OA, BS |
| Gcnf | BC, H, AN, CO, C, BS |
| Ear2 | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Errα | OA, BC, H, HY, CO, C, BS |
| Errβ | BC, H, HY, CO, C, BS |
| Errγ | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Gr | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Pr | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Car | OA, BC, HY, C, BS |
| Erα | OA, BC, H, HY, AN, CO, C, BS |
| Erβ | OA, BC, HY, AN, CO, BS |
| Ar | OA, BC, H, HY, CO, C, BS |
| Shp | OA, BC, H, T, HY, AN, CO, C, BS |
| Fxrα | OA, BC, CP, H, T, HY, AN, CO, C, BS |
| Trb | T |
| Dax1 | HY, AN |
| Sf-1 | HY |
| Lrh-1 | AN, BS |
Abbreviations: BC, brain cortex; C, cerebellum; BS, brain stem; OA, olfactory areas; CP, caudate putamen; H, hyppocamps; T, thalamus; HY, hypothalamus; AN, arcuate nucleus; CO, colliculi.
Knockout mice models excising that effect the CNS function.
| MODEL NAME | BRAIN/EYE DEFECTS |
|---|---|
| Thrb | – Lack of M-opsin expressing cones. |
| – S cone gradient in the retina disturbed. | |
| TRβ mut | – Impairment in balance and coordination. |
| – Reduce cerebellum mass. | |
| – Decrease in Purkinje cell layer. | |
| Rorasg | – Deficiency of granule cells and Purkinje cells. |
| – Cerebellar cortex underdeveloped. | |
| Nr4a2 | – Failure to develop dopaminergic neurons. |
| Nr2e3 | – White spots evenly distributed in the retina. |
| – Whorls and rossetts can be detected in the retina –Progressive loss of cones and rods. | |
| Rorβ−/− | – Loss of rods. |
| – Overproduction of primitive S cones. | |
| Nr1d1tm1Ven | – Delay cerebellum development. |
| – Abnormal Purkinje ad granule cells. | |
| RAR β2 γ2−/− | – Marked atrophy and dysplasia of the retina. |
| – In the central retina only 2 or 3 rows of nuclei are found. | |
| RXRα−/− and RXR β−/− | – Fetus diet at E12.5–16.5. |
| – Fetus have conotruncal and ocular defects. | |
| – Failure to close the neural tube. | |
| TLX KO | – Thickness of the retina is reduces. |
| – Increased number of apoptotic cells in the inner nuclear layer of the retina. | |
| – Decreased proportion of mitotic cells. | |
| Rarbtm2Ipc|Rargtm3Ipc |Tg (Wnt1-cre)11Rth | – Severe ocular abnormalities. |
| Rxratm4Ipc|Tg (Tyrp1-cre)1Ipc | – Decreased number of photoreceptors. |
| – Abnormal photoreceptor outer segment morphology. | |
| – Reduce light response. | |
| Nr1h2tm1.1Gstr|Nr1h3tm1.1Gstr | – Abnormal astrocyte morphology. |
| – Abnormal brain vasculature morphology. |
Figure 5List of NHRs involved in the differentiation of the mitotic progenitor cells and the retinal cell types. Genes marked in bold correspond to NHRs unique for each cell type.
Nuclear hormone receptor and associated diseases in humans.
| GENE | HUMAN DISEASE | OMIM ID |
|---|---|---|
| Nr1b2 (RAR-β) | Syndromic microphthalmia | 615524 |
| Schizophrenia | 181500 | |
| Nr1c1 (PPAR-α) | Alzheimer’s disease | 104300 |
| Nr2c2 (Tr4) | Deficit in motor coordination | |
| Nr2e3 (Pnr) | Enhanced S cone syndrome | 268100 |
| Retinitis pigmentosa | 611131 | |
| Nr2f1 (Coup-TFI) | Bosch-Boonstra optic atrophy syndrome | 615722 |
| Nr3a1 (ER α) | Migraine | 157300 |
| Nr3a2 (ER-β) | Alzheimer’s disease | 104300 |
| Nr3c1 (GR) | Depression | 608520 |
| Nr3c2 | Stress | |
| Nr3c3 (PR) | Vertigo | 193007 |
| Nr4a2 | Parkinson disease | 300557 |